Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations and Comprehensive Loss

v3.20.1
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Mar. 31, 2020
Mar. 31, 2019
Condensed Consolidated Statements of Operations and Comprehensive Loss        
Revenues $ 96 $ 527 $ 518 $ 1,223
Operating expenses:        
Research and development (related party of $0, $217, $97 and $761), net of grant income of $0, $0, $0 and $37, respectively 999 1,453 2,864 3,850
General and administrative (related party of $316, $288, $941 and $860) 3,161 2,844 8,728 9,108
Total operating expenses 4,160 4,297 11,592 12,958
Operating loss (4,064) (3,770) (11,074) (11,735)
Other income (expense):        
Interest expense - related party (616) (474) (1,851) (1,426)
Interest income 4 20 12 64
Royalty income     9 4
Total other income (expense) (612) (454) (1,830) (1,358)
Consolidated net loss (4,676) (4,224) (12,904) (13,093)
Net loss attributable to noncontrolling interest   1 3 3
Net loss attributable to iBio, Inc. (4,676) (4,223) (12,901) (13,090)
Deemed dividends - down round of Series A Preferred and Series B Preferred 0 0 (21,560) 0
Preferred stock dividends- iBio CMO Preferred Tracking Stock (65) (64) (196) (195)
Net loss available to iBio, Inc. (4,741) (4,287) (34,657) (13,285)
Comprehensive loss:        
Consolidated net loss (4,676) (4,224) (12,904) (13,093)
Other comprehensive loss - foreign currency translation adjustments   (1) (2) 0
Comprehensive loss $ (4,677) $ (4,224) $ (12,906) $ (13,093)
Loss per common share attributable to iBio, Inc. stockholders - basic and diluted $ (0.06) $ (0.22) $ (0.74) $ (0.71)
Weighted-average common shares outstanding - basic and diluted 79,917 19,224 47,018 18,597